
<u>Subject:</u>	<u>Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders</u>	<u>Publish Date:</u>	<u>06/28/2023</u> 07/06/2022
<u>Policy #:</u>	<u>MED.00090</u>	<u>Last Review Date:</u>	<u>05/12/2023</u>

Description/Scope

This document addresses a wireless capsule for the evaluation of suspected gastric and intestinal motility disorders (SmartPill™ Motility Testing System [Medtronic, Minneapolis, MN]). The capsule was designed to measure pH, temperature and pressure throughout the gastrointestinal tract and transmits measurements via radio signals to an external recording device. In the stomach, the SmartPill has been used to assess gastric emptying in individuals with suspected gastroparesis. In the intestine, the SmartPill has been used to assess small and large bowel transit times in those with chronic constipation or other motility disorders. The device is also referred to in this document as a wireless motility capsule (WMC).

Note: Please see the following related document for additional information:

- CG-MED-70 Wireless Capsule Endoscopy for Gastrointestinal Imaging and the Patency Capsule

Position Statement

Investigational and Not Medically Necessary:

A wireless capsule (SmartPill Motility Testing System) is considered investigational and not medically necessary for evaluation of all conditions including, but not limited to the following:

- 1. Suspected gastric motility disorders; or
- 2. Suspected intestinal motility disorders.

Rationale

Wireless Motility Capsule for the Evaluation of Suspected Gastroparesis

An early study evaluating WMC was published by Kuo and colleagues in 2008. The study enrolled 87 healthy subjects and 61 individuals with known gastroparesis. Participants simultaneously ingested the wireless capsule and a radiolabeled meal, permitting a head-to-head comparison. The investigators did not indicate whether outcomes were interpreted in a blinded fashion. At 4 hours, the correlation between the two techniques was 0.73, which exceeded the prespecified target correlation. In a secondary analysis of data from 100 study participants, reported

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

© CPT Only – American Medical Association

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

by Sarosiek and colleagues (2010), gastric emptying time (GET), colon transit time (CTT) and whole gut transit times (WGTT) but not small bowel transit time (SBTT) were noted to be longer in gastroparetics than in healthy controls. This study was limited in that it did not include individuals with suspected gastroparesis, the population of interest.

A 2013 comparative effectiveness review by the Agency for Healthcare Research and Quality (AHRQ) identified seven studies comparing WMC and gastric emptying scintigraphy (GES) for diagnosing gastroparesis. Although the AHRQ report found that the diagnostic accuracy of WMC and GES were similar, the strength of evidence was determined to be low which indicated “low confidence that the evidence reflects the true effect”. The main limitations contributing to the low strength of the evidence were that participant eligibility criteria and criteria for positive test findings were not clearly pre-specified. Moreover, most studies had limited durations of follow-up.

Hasler and colleagues (2017) compared WMC and GES in individuals with suspected gastroparesis, but did not report diagnostic accuracy or the impact on management decisions or health outcomes. In the study, 209 individuals with gastroparesis symptoms for at least 12 weeks with no evidence of organic disease underwent WMC and GES on different days. Individuals ceased taking medications prior to WMC testing. Blinding was not discussed. The overall agreement between GET and delayed 4-hour scintigraphic retention was 52.8% (kappa, 0.12). Agreement between GET and 2-hour scintigraphic retention was 58.7% (kappa, 0.16). The study investigators noted that device agreement was lower than that in the earlier study by Kuo and colleagues (2008), discussed above, and hypothesized that this difference may be due in part to the tests being performed on separate days in the current investigation whereas they were done on the same day in the Kuo study.

Several studies have compared simultaneous WMC and GES in individuals with suspected gastroparesis. In 2019, Lee and colleagues reported on delayed gastric emptying time in 167 individuals with gastroparesis who were assessed simultaneously by WMC and GES. Delayed gastric emptying by WMC was defined as more than 5 hours before passage of the capsule into the duodenum and delayed emptying by GES was defined as at least 10% meal retention at 4 hours. Delayed gastric emptying time by WMC occurred in 53 individuals (34.6%) and delayed gastric emptying by GES occurred in 39 individuals (24.5%). There was an overall device agreement between WMC and GES of 75.7%. Severely delayed gastric emptying was identified in 21 individuals (13.8%) by WMC and 11 individuals (7%) with GES. Agreement between WMC and GES for severe delayed gastric emptying was 38%. Significantly higher proportions of individuals with delayed and severely delayed emptying were identified by WMC.

In 2020, Sangnes and colleagues reported on 72 individuals with diabetes mellitus and suspected gastroparesis. The correlation between WMC and 4-hour GES was $r=0.74$ ($p<0.001$). At a cutoff of 300 minutes for gastric emptying time with WMC, the sensitivity compared with GES was 0.92 (95% confidence interval [CI], 0.74 to 0.99) and the specificity was 0.73 (95% CI, 0.57 to 0.86). The investigators found that the optimal cutoff for WMC was 385 minutes, for which the sensitivity was 92% (95% CI, 0.74 to 0.99) and the specificity was 0.83 (95% CI, 0.68 to 0.93). Although they included the population of interest, the Lee and Sangnes studies did not address the impact of diagnosis by WMC and GES on patient management or health outcomes.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

© CPT Only – American Medical Association

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

Wireless Motility Capsule for the Evaluation of Suspected Chronic Constipation

Chronic constipation may be associated with a prolonged CTT or WGTT, both of which are typically measured using radiopaque markers (ROM). Validation of the wireless motility capsule to evaluate CTT or WGTT requires directly comparative studies with conventional ROM and blinded interpretation of results. In addition, the diagnosis of chronic constipation is based predominantly on clinical symptoms; therefore, studies should ideally document how measurements of transit times contribute to management of the condition (i.e., clinical utility).

A study by Camilleri and colleagues (2010) compared the wireless motility capsule to ROM measurements of colon transit. Of the 208 subjects recruited 180 individuals with self-reported symptoms of constipation were enrolled in the multicenter trial. The study participants ingested both the wireless motility capsule and ROM. After exclusions and missing data, the assessment of CTT was based on comparisons between WMC and ROM in 157 subjects, and comparison between small and large bowel transit time (SLBTT) by WMC and ROM in 154 subjects. Study results indicated that 59 of 157 subjects had delayed ROM colon transit. Overall device agreement was reported as 86%. There were correlations reported between ROM and WMC transit and between ROM and combined SLBTT. Estimates of CTT and SLBTT were calculated by a team reported as being blinded to the ROM transit results. Adverse events reported during the trial included the inability of 2 subjects to swallow the wireless motility capsule and 1 case each of abdominal cramping, nausea and loose or soft stools recorded as possibly related to the wireless motility capsule. The authors noted potential pitfalls of using all capsules to measure gut transit, including: “technical failures, inability to swallow the capsule, the potential for non-passage of or intestinal obstruction by the capsule in stenosing gut disorders, and greater cost relative to the ROM transit method.”

A smaller study by Rao and colleagues (2009) compared transit times in both constipated (n=78) and healthy subjects (n=87) measured simultaneously with the WMC and ROM. The WMC estimated the SBTT based on pH changes as the capsule entered the duodenum (increase in pH) and then passed into the cecum (decrease in pH). The CTT was based on the time interval between entry into the cecum and the capsule exit from the body. Serial plain abdominal films were used to assess the movement of ROM. Correlation of the wireless motility capsule’s colonic transit with ROMs expelled on day 2/day 5 was $r=0.74/r=0.69$ in the constipated subjects, and $r=0.70/r=0.40$ in the control group, respectively. This study did not report whether or not the results were interpreted in a blinded fashion, and there was no discussion of how the diagnostic information was used in the management of the condition.

A 2013 comparative effectiveness review by the AHRQ identified five studies comparing WMC and ROM for diagnosing slow-transit constipation. Although the AHRQ report found that the diagnostic accuracy of WMC and ROM were similar, the strength of evidence (SOE) was determined to be low which indicated “low confidence that the evidence reflects the true effect”. The determination of low SOE was due to several factors including the retrospective nature of the studies, uncertainty that the studies included the appropriate spectrum of participants, limited follow-up duration of most studies and unclear blinding of outcomes.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

Wireless Motility Capsule for the Evaluation of Suspected Upper and Lower Gastrointestinal (GI) Motility Disorders

Several retrospective studies have been published. Rao and colleagues (2011a) evaluated the WMC in 86 individuals with suspected upper and lower gastrointestinal dysmotility. To be eligible, subjects needed to have symptoms of dysmotility (abdominal pain, nausea, vomiting, bloating, fullness after meals, constipation, straining, or feeling of incomplete evacuation) and normal endoscopic/radiologic evaluations. The diagnostic utility of the WMC was retrospectively assessed by examining device agreement and new information compared with conventional motility tests. Study subjects were classified into two subgroups on the basis of major symptom(s): lower GI (n=50) and upper GI (n=36). Clinical suspicion was confirmed in 52% and 66% of study subjects, respectively, and the authors stated there was good device agreement between the wireless motility capsule and conventional tests in 76% and 81% in the lower GI and upper GI groups, respectively. There was new diagnostic information with the wireless motility test in 53% of the lower GI (p=0.006) and 47% of the upper GI group (p=0.001). The wireless motility capsule detected generalized motility disorder in 44 (51%) subjects and influenced management in 30% of lower GI and 88% of upper GI subjects. Study limitations noted by the authors included potential bias of a retrospective study, the inclusion of subjects with more severe symptoms than are typically seen at a tertiary care center, and the tests were not carried out simultaneously which could result in discrepancy between the test results.

Kuo and colleagues (2011) evaluated the WMC in a retrospective study of 83 subjects with suspected gastroparesis, intestinal dysmotility, or slow transit constipation. Databases at two referral centers for gastrointestinal motility were accessed. Wireless motility capsule transits were analyzed and isolated regional delays were observed in 32% (9% stomach, 5% small bowel, 18% colon). Transits were normal in 32% and showed generalized delays in 35%. Symptom profiles were similar with normal transit, isolated delayed gastric, small intestinal and colonic transit, and generalized delay. Compared to conventional tests, WMC showed discordance in 38% and provided new diagnoses in 53%. Wireless motility testing reportedly influenced clinical management in 65 subjects (67%) (new medications 60%; modified nutritional regimens 14%; surgical referrals 6%) and eliminated needs for testing not already done including gastric scintigraphy (17%), small bowel barium transit (54%), and radiopaque colon marker tests (68%). A limitation of this study was that all subjects were from two academic centers specializing in managing severe dysmotility syndromes and would therefore differ from a representative community sample. Also of note, this retrospective investigation involved analyses of preexisting databases and data recording was not standardized, therefore reporting of a lack of a specific symptom or test result may not be the equivalent of symptom absence or non-performance of the test.

Arora and colleagues (2015) performed a single center retrospective chart review of 161 individuals who underwent wireless motility capsule testing. Wireless motility capsule testing was abnormal in 109 (67.7%) subjects. From the abnormal cases, 17 (15.6%) individuals had isolated delayed gastric emptying, 13 (11.9%) had isolated delayed small bowel transit, and 25 (22.9%) had isolated delayed large bowel transit. Multiregional (upper and lower) dysmotility was diagnosed in 54 (49.5%) cases. Of note, the presence or absence of various individually-reported symptoms by history did not predict an abnormal study. The authors concluded that “wireless motility capsule can be a useful diagnostic test in patients with suspected multiregional GI dysmotility.” However, they also reported

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

© CPT Only – American Medical Association

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

that a limitation of the study was that they “did not attempt to assess if the results of the wireless motility capsule study changed the patients’ outcome or management as the information needed was difficult to obtain in our settings and may be unreliable.”

A retrospective chart review of 100 people with diabetes who had undergone wireless motility capsule testing at a single institution between the years 2010 to 2015 was performed by Rouphael and colleagues (2017). Of the original 103 subjects, 3 were excluded due to either a retained capsule (n=1) or missing data secondary to device failure (n=2). A total of 72% of subjects had abnormal wireless motility capsule testing, of which 40% (n=29) had multiregional dysmotility with 6.9% (n=5) having delayed transit in all three GI tract segments. Information related to subsequent clinical management post testing was available for 47 subjects. The remaining 53 subjects were excluded from the analysis due to loss to follow-up or incomplete information related to treatment change or response to therapy. Of the 47 subjects, wireless motility capsule testing was abnormal in 70% (n=33) and treatment changes were made in 73% (n=24) of those with gut dysmotility. Limitations of this study included the retrospective nature of the analysis and small sample size.

Rodriguez and colleagues (2021) reported on a prospective series in 57 children age 8 to 18 years who underwent WMC evaluation of upper or lower GI symptoms. A total of 34 individuals also underwent a nuclear medicine gastric emptying study (NMGET) and 21 underwent a colonic radiopaque marker (CROM) transit study. The overall agreement between WMC and NMGET tests was 70%. In 8 individuals, there was an abnormal gastric residency time (GRT) with WMC and a normal NMGET, and GRT was normal in 2 individuals who had an abnormal NMGET. There was an overall agreement of 81% between WMC and CROM studies. A total of 4 individuals had an abnormal CROM study and a normal colonic transit time with WMC, and 1 individual had an abnormal colonic transit time with WMC and a normal CROM. Capsule prolonged retention (beyond 5 days) occurred in 9 individuals; at 2 weeks after the study, all of the capsules had been expelled. The study did not evaluate the ability of the WMC to predict health outcomes.

Other Considerations

A position paper of the American and European Neurogastroenterology and Motility Societies (Rao, 2011b), reviewed diagnostic tools used to assess regional or WGTT including the wireless motility capsule. The paper recommended the wireless motility capsule for the following:

- Assessment of gastric emptying and regional and WGTT in individuals with suspected gastroparesis and symptoms of upper GI dysmotility
- To facilitate detection of small bowel dysfunction in subjects with a more generalized GI motility disorder
- Assessment of CTT in subjects with constipation and those with suspected colonic disorders

Confounding issues or disadvantages involving the wireless motility capsule reported in the position paper included:

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

© CPT Only – American Medical Association

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

- Requires ingestion of a large capsule and wearing/returning a data receiver for up to five days if WGTT is being assessed
- Risk of capsule retention (20/2000 cases [0.33%] as of January 2010) which required endoscopic removal in two cases
- Use is contraindicated in those with pseudo-obstruction, ileus and gastric bezoar
- SBTT is not possible in some subjects, as pH landmarks cannot be accurately identified
- Requires physician training for interpretation, and device failure has been reported
- Has not yet been tested for colonic responsiveness to pharmacological agents

The American Gastroenterological Association (AGA) clinical practice guideline on management of medically refractory gastroparesis (Lacy, 2022) does not specifically have any best practice recommendations on use of wireless motility capsule. Their best practice advice includes the following: “clinicians should verify appropriate methodology of the gastric emptying study to ensure an accurate diagnosis of delayed gastric emptying”, and “clinicians should classify patients with gastroparesis into mild, moderate, or severe based on symptoms and the results of a properly performed gastric emptying study”.

Regarding the wireless motility capsule, the discussion in the guideline states:

Because the wireless motility capsule, an inanimate object, identifies the phase III activity front of the migrating motor complex rather than overall gastric emptying, a meal-based test provides better physiological assessment of gastric emptying and is thus recommended as the first-line test of gastric emptying over the wireless motility capsule.

The recommendations made by professional societies regarding the wireless motility capsule are limited because there is insufficient supporting evidence to fully establish the clinical utility or accuracy of the SmartPill. In addition, significant confounding issues or disadvantages of the device have been reported.

Conclusion

Studies evaluating the usefulness of wireless motility capsule testing in suspected gastric motor disorders have been limited by study design limitations and some studies have small sample sizes. Larger well designed studies are needed that compare results with use of this device (using an established protocol and cutoff values) with the current standard test. Evaluation of cases with discordant results would be of particular value. Ideally, these studies should be linked to therapeutic decisions and to meaningful clinical outcomes.

Background/Overview

Gastroparesis is a “syndrome of objectively delayed gastric emptying in the absence of mechanical obstruction and cardinal symptoms...” The symptoms include “early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain.” Similar symptoms can be present with other conditions such as peptic ulcer and functional

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

dyspepsia and thus the combination of symptoms and documentation of delayed gastric emptying is needed to confirm the diagnosis of gastroparesis. Gastric emptying scintigraphy of a solid-phase meal is considered the standard method of identifying delayed gastric emptying and gastric retention at 4 hours is the most reliable parameter with which to quantify gastric emptying. Breath testing, such as those that use ¹³C-octanoate or ¹³C-spirulina, are a potential alternative to gastric emptying scintigraphy. However, an American College of Gastroenterology 2013 clinical guideline states that breath tests require additional validation (Camilleri, 2013).

Another potential option for evaluation of suspected gastroparesis is use of a WMC. A WMC device, known as the SmartPill Motility Testing System (Medtronic), has been cleared for marketing by the U.S. Food and Drug Administration (FDA). According to the FDA 510(k) documents, the SmartPill is indicated for use in evaluating individuals with suspected delayed gastric emptying (gastroparesis) as well as for the evaluation of colonic transit in those with chronic constipation. The SmartPill measures pH, pressure and temperature throughout the gastrointestinal tract. This data is then transmitted from the capsule via radio signal to an individually-worn data receiver and downloaded to a computer in the physician's office for analysis and review. The recorded physiological measurements are used to determine GET, total transit time, and combined small-large bowel transit time. In addition, pressure contraction patterns from the antrum and duodenum are used to calculate motility indices.

Definitions

Gastric Emptying Scintigraphy (GES): A type of test which uses a radio-labeled meal to measure gastric emptying.

Gastroparesis: A condition where there is delayed gastric emptying and characteristic gastrointestinal symptoms.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When Services are Investigational and Not Medically Necessary:

For the following procedure code, or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

CPT

91112

Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report

ICD-10 Diagnosis

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

© CPT Only – American Medical Association

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

All diagnoses

References

Peer Reviewed Publications:

1. Arora Z, Parungao JM, Lopez R, et al. Clinical utility of wireless motility capsule in patients with suspected multiregional gastrointestinal dysmotility. Dig Dis Sci. 2015; 60(5):1350-1357.
2. Camilleri M, Thorne NK, Ringel Y, et al. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil. 2010; 22(8):874-882, e233.
3. Hasler WL, May KP, Wilson LA, et al. Relating gastric scintigraphy and symptoms to mobility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol Motil. 2018; 30(2): 1-12.
4. Hasler WL. The use of SmartPill for gastric monitoring. Expert Rev Gastroenterol Hepatol. 2014; 8(6):587-600.
5. Hasler WL, Coleski R, Chey WD, et al. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol. 2008; 294(6):G1384-1391.
6. Kuo B, Maneerattanaporn M, Lee AA, et al. Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig Dis Sci. 2011; 56(10):2928-2938.
7. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008; 27(2):186-196.
8. Lee AA, Rao S, Nguyen LA et al. Validation of diagnostic and performance characteristics of the wireless motility capsule in patients with suspected gastroparesis. Clin Gastroenterol Hepatol. 2019; 17(9):1770-1779.
9. Parkman HP. Assessment of gastric emptying and small-bowel motility: scintigraphy, breath tests, manometry, and SmartPill. Gastrointest Endosc Clin N Am. 2009; 19(1):49-55, vi.
10. Rao SS, Kuo B, McCallum RW, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol. 2009; 7(5):537-544.
11. Rao SS, Mysore K, Attaluri A, Valestin J. Diagnostic utility of wireless motility capsule in gastrointestinal dysmotility. J Clin Gastroenterol. 2011a; 45(8):684-690.
12. Rodriguez L, Heinz N, Colliard K et al. Diagnostic and clinical utility of the wireless motility capsule in children: A study in patients with functional gastrointestinal disorders. Neurogastroenterol Motil. 2021; 33(4):e14032.
13. Rouphael C, Arora Z, Thota PN, et al. Role of wireless motility capsule in the assessment and management of gastrointestinal dysmotility in patients with diabetes mellitus. Neurogastroenterol Motil. 2017; 29 (9).
14. Sangnes DA, Søfteland E, Bekkelund M et al. Wireless motility capsule compared with scintigraphy in the assessment of diabetic gastroparesis. Neurogastroenterol Motil. 2020; 32(4):e13771.
15. Sarosiek I, Selover KH, Katz LA, et al. The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. Aliment Pharmacol Ther. 2010; 31(2):313-322.

Government Agency, Medical Society, and Other Authoritative Publications:

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

1. Camilleri M, Parkman HP, Shafi MA, et al. American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013; 108(1):18-37.
2. Lacy BE, Tack J, Gyawali CP. AGA Clinical practice update on management of medically refractory gastroparesis: Expert review. Clin Gastroenterol Hepatol. 2022; 20(3):491-500.
3. Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011b.
4. Stein E, Berger Z, Hutfless S, et al. Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation: A Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 May. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK154643/>. Accessed on March 15, 2023.
5. U.S. Food and Drug Administration. 510(k) Summary: K053547. January 10, 2017. Available at: www.accessdata.fda.gov/cdrh_docs/pdf5/k053547.pdf. Accessed on March 15, 2023.

Websites for Additional Information

1. American College of Gastroenterology. Gastroparesis. Available at: <https://gi.org/topics/gastroparesis/>. Accessed on March 15, 2023.
2. American Neurogastroenterology and Motility Society. Information on GI motility tests and procedures Available at: <https://motilitysociety.org/page.php?id=238>. Accessed on March 15, 2023.

Index

- SmartPill GI Monitoring System
- SmartPill Motility Testing System
- Wireless Capsule for Measuring Gastric Emptying
- Wireless Motility Capsule (WMC)

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Document History

Status	Date	Action
Revised	05/11/2023	Medical Policy & Technology Assessment Committee (MPTAC) review. Revised hierarchy formatting in the INV/NMN statement. Updated Rationale and References sections updated.
Reviewed	05/12/2022	Medical Policy & Technology Assessment Committee (MPTAC) review. Rationale and References sections updated.
Revised	05/13/2021	MPTAC review. Reformatted Position Statement to single INV/NMN statement with bullet points. Rationale and References sections updated.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

<u>Reviewed</u>	<u>05/14/2020</u>	<u>MPTAC review. Rationale and References sections updated. In Description/Scope, added cross-reference to CG-MED-70 Wireless Capsule Endoscopy for Gastrointestinal Imaging and the Patency Capsule.</u>
<u>Reviewed</u>	<u>06/06/2019</u>	<u>MPTAC review. Rationale and References sections updated.</u>
<u>Reviewed</u>	<u>07/26/2018</u>	<u>MPTAC review. The document header wording updated from “Current Effective Date” to “Publish Date”. Rationale, Background/Overview, Definitions and References sections updated.</u>
<u>Reviewed</u>	<u>08/03/2017</u>	<u>MPTAC review. Rationale and References sections updated.</u>
<u>Revised</u>	<u>08/04/2016</u>	<u>MPTAC review. Description, Rationale, Background, Reference and Index sections updated. Position statement updated with new device name (SmartPill GI Monitoring System changed to SmartPill Motility Testing System). Removed ICD-9 codes from Coding section.</u>
<u>Reviewed</u>	<u>08/06/2015</u>	<u>MPTAC review. Description, Rationale, Background and Reference sections updated.</u>
<u>Reviewed</u>	<u>08/14/2014</u>	<u>MPTAC review. Description, Rationale and Reference sections updated.</u>
<u>Reviewed</u>	<u>08/08/2013</u>	<u>MPTAC review. Rationale and Reference sections updated.</u>
	<u>01/01/2013</u>	<u>Updated Coding section with 01/01/2013 CPT changes; removed 0242T deleted 12/31/2012.</u>
<u>Reviewed</u>	<u>08/09/2012</u>	<u>MPTAC review. Rationale, Reference and Index sections updated.</u>
<u>Reviewed</u>	<u>08/18/2011</u>	<u>MPTAC review. Rationale, Definition and Reference sections updated.</u>
<u>Reviewed</u>	<u>08/19/2010</u>	<u>MPTAC review. Updated title of document by removing brand name. Clarified initial position statement by adding the word “motility”. Description, Rationale, Background, References and Index updated. Updated Coding section with CPT changes effective 01/01/2011.</u>
<u>Revised</u>	<u>11/19/2009</u>	<u>MPTAC review. Description, rationale coding and references updated. Original position statement updated to address a wireless capsule for the evaluation of suspected gastric disorders. Added a position statement to address a wireless capsule for the evaluation of suspected intestinal motility disorders. Updated title of document to include intestinal motility.</u>
<u>Reviewed</u>	<u>11/20/2008</u>	<u>MPTAC review. Position statement clarified by adding the wording “A wireless capsule for measuring gastric emptying” to describe SmartPill GI Monitoring System. No change to position stance. Description, rationale, references, and index updated. Definitions added. Title of document changed from “SmartPill GI Monitoring System[®]” to “Wireless Capsule for Measuring Gastric Emptying (SmartPill GI Monitoring System[®])”.</u>
<u>Reviewed</u>	<u>11/29/2007</u>	<u>MPTAC review. Rationale and references updated. The phrase “investigational/not medically necessary” was clarified to read “investigational and not medically necessary.”</u>
<u>New</u>	<u>12/07/2006</u>	<u>MPTAC initial document development.</u>

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.